Determinants of Infection Outcome in HCV-Genotype 4

被引:5
作者
Zayed, Rania A. [1 ]
Omran, Dalia [2 ]
Zayed, Abeer A. [3 ]
Elmessery, Lobna O. [1 ]
机构
[1] Cairo Univ, Dept Clin & Chem Pathol, Fac Med, El Saraya St, Giza 11451, Egypt
[2] Cairo Univ, Dept Endem Med & Hepatogastroenterol, Fac Med, Giza, Egypt
[3] Cairo Univ, Dept Forens Med & Clin Toxicol, Fac Med, Giza, Egypt
关键词
HCV-4; epidemiology; natural history; treatment; HEPATITIS-C-VIRUS; SUSTAINED VIROLOGICAL RESPONSE; SOFOSBUVIR PLUS RIBAVIRIN; TRANSFUSION-ASSOCIATED HEPATITIS; BLOOD MONONUCLEAR-CELLS; HEPATOCELLULAR-CARCINOMA; LIVER FIBROSIS; OPEN-LABEL; POSTTRANSFUSION HEPATITIS; MOLECULAR EPIDEMIOLOGY;
D O I
10.1089/vim.2017.0071
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis C virus (HCV) infection represents a worldwide health problem and has been for long an attractive point of research due to diversity among different genotypes regarding unique geographical distribution and diverse treatment outcome. HCV is considered a major cause of chronic liver disease and cirrhosis, which leads to liver failure and hepatocellular carcinoma requiring liver transplantation. Of the HCV genotypes identified, HCV genotype 4 (HCV-4) is the least studied. HCV-4 is responsible for approximate to 10% of HCV infections and is common in the Middle East and Africa; recently it is increasingly prevalent in European Countries. HCV-4 is a continuing epidemic in Egypt, having the highest prevalence of HCV worldwide. Know your epidemic, know your response concept necessitates better understanding of HCV-4 characteristics to control disease dissemination and progression, which compromises the life quality of chronic HCV-infected patients. In this review, we discuss the epidemiology, natural history, and treatment options for patients with HCV-4 infection.
引用
收藏
页码:560 / 567
页数:8
相关论文
共 114 条
[1]   Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study [J].
Abergel, Armand ;
Asselah, Tarik ;
Metivier, Sophie ;
Kersey, Kathryn ;
Jiang, Deyuan ;
Mo, Hongmei ;
Pang, Phillip S. ;
Samuel, Didier ;
Loustaud-Ratti, Veronique .
LANCET INFECTIOUS DISEASES, 2016, 16 (04) :459-464
[2]   Hepatitis C Genotype 4: Genotypic Diversity, Epidemiological Profile, and Clinical Relevance of Subtypes in Saudi Arabia [J].
Al Ashgar, Hamad I. ;
Khan, Mohammed Q. ;
Al-Ahdal, Mohammed ;
Al Thawadi, Sahar ;
Helmy, Ahmad Salem ;
Al Qahtani, Ahmed ;
Sanai, Faisal M. .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2013, 19 (01) :28-33
[3]  
[Anonymous], 1996, MED COMMUNITY, V6, P1
[4]  
[Anonymous], Recommendations for testing, managing, and treating hepatitis C
[5]  
[Anonymous], 1999, J HEPATOL S1, V31, P3
[6]   Different seroprevalence and molecular epidemiology patterns of hepatitis c virus infection in Italy [J].
Ansaldi, F ;
Bruzzone, B ;
Salmaso, S ;
Rota, MC ;
Durando, P ;
Gasparini, R ;
Icardi, G .
JOURNAL OF MEDICAL VIROLOGY, 2005, 76 (03) :327-332
[7]   The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province [J].
Antaki, N. ;
Haddad, M. ;
Kebbewar, K. ;
Abdelwahab, J. ;
Hamed, O. ;
Aaraj, R. ;
Alhaj, N. ;
Haffar, S. ;
Assil, M. ;
Ftayeh, M. ;
Assaad, F. ;
Doghman, D. ;
Ali, T. ;
Nasserelddine, M. ;
Ali, A. ;
Antaki, F. .
EPIDEMIOLOGY AND INFECTION, 2009, 137 (01) :79-84
[8]   A RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR CO-ADMINISTERED WITH RIBAVIRIN IN ADULTS WITH GENOTYPE 4 CHRONIC HEPATITIS C INFECTION AND CIRRHOSIS [J].
Asselah, T. ;
Hassanein, T. ;
Qaqish, R. B. ;
Feld, J. J. ;
Hezode, C. ;
Zeuzem, S. ;
Ferenci, P. ;
Pilot-Matias, T. ;
Yu, Y. ;
Mobashery, N. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S861-S861
[9]   Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping [J].
Bdour, S .
JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 51 (08) :700-704
[10]  
Chang TT, 1996, HEPATOLOGY, V23, P977